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Purinoceptors mediate renal vasodilation by nitric oxide
dependent and independent mechanisms
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Purinoceptors mediate renal vasodilation by nitric oxide depen-
dent and independent mechanisms.
Background. Adenosine triphosphate (ATP) and its metabolites
including adenosine modulate renal vascular tone under physio-
logical and pathophysiological conditions. Their effects are
brought about by activation of membrane bound P1- and P2-
purinoceptors located on smooth muscle and endothelial cells. In
this study we analyzed the purinoceptor mediated dilation of
rabbit and human renal arteries, and evaluated the possible
involvement of endothelium-derived relaxing factors.
Methods. Segments of rabbit and human renal arteries were
incubated and perfused with medium containing indomethacin.
After preconstriction, drug induced changes in the vessel diame-
ters were measured by a photoelectric device.
Results. ATP (EC50 5 1 mmol/liter), added intraluminally,
caused maximal vasodilation of 80 to 100% of the preconstriction
response in both species. This effect was inhibited by the P1-
purinoceptor antagonist 8-p-(sulphophenyl)theophylline (100
mmol/liter), suggesting that it was in part due to breakdown of
ATP to adenosine. The nature of purinoceptor mediated renal
vasodilation was studied further in rabbit renal arteries. Adeno-
sine (EC50 5 1 mmol/liter) as well as the P2Y-receptor agonists
ADPbS (EC50 5 0.4 mmol/liter) and 2-MeSATP (EC50 5 0.2
mmol/liter) dilated the arteries by 80 to 100%. The effects of
2-MeSATP, which were to a much lesser extent that of ADPbS
but not that of adenosine, were attentuated by the P2Y-antagonist
reactive blue 2 (3 mmol/liter). Removal of the endothelium almost
abolished the vasodilation induced by adenosine and ATP. In
contrast, these dilator responses were only slightly attenuated by
the nitric oxide synthase blockers NG-nitro-L-arginine methyl
ester and NG-nitro-L-arginine (300 mmol/liter each), whereas
acetylcholine and 2-MeSATP induced dilation was markedly
reduced by NG-nitro-L-arginine methyl ester.
Conclusions. P1-purinoceptors activated by adenosine dilate
rabbit renal arteries by an endothelium-derived relaxing factor
that appears to be distinct from nitric oxide. In contrast, P2Y-
purinoceptor induced renal dilation is mediated by nitric oxide.
ATP, the physiological activator of P2Y-purinoceptors, is rapidly
broken down to adenosine in rabbit and human renal arteries.
Therefore, in rabbit and human renal arteries the vasodilatory
effect of exogenous ATP mainly results from P1-purinoceptor
activation probably through its breakdown product, adenosine.
Adenosine triphosphate (ATP) and its metabolites in-
cluding adenosine have been shown to play an important
role in the control of renal blood flow under physiological
and pathophysiological conditions [1–6]. The purine com-
pounds can act directly upon specific membrane-bound
receptors on smooth muscle cells to cause either vasocon-
striction or vasodilation, but may also have indirect effects
on blood vessel tone. Accordingly, purines have been
shown to modulate renin secretion from juxtaglomerular
cells and to release vasoactive mediators from endothelial
cells [7, 8].
The effects of adenosine on renal blood vessels are
mediated predominantly by an action on P1-receptors of
the A1- and A2-subtypes. Activation of A1-receptors causes
constriction of afferent arterioles, whereas activation of
A2-receptors causes dilation of proximal and distal renal
blood vessels [9–11]. P1-receptors may be also involved in
the vascular effects of adenine nucleotides in the kidney,
since the nucleotides are broken down enzymatically to
adenosine. However, a significant part of the nucleotide
effects on renal blood vessel tone is mediated by a direct
action on P2-receptors [5, 12]. Two classes of P2-receptors,
P2X- and P2Y-receptors, exist, both of which have multiple
subtypes that have already been cloned [13, 14]. P2X-
receptors mediate direct constrictor effects of nucleotides
in renal arteries of several species [10, 15–19] including
those of humans [20]. In contrast, P2Y-receptors are known
to mediate vasodilator effects of nucleotides in various
vascular beds [2, 21, 22].
Only limited information is available about vasodilator
mechanisms of adenine nucleotides in renal blood vessels.
In the rat kidney, P2Y-receptor mediated vasodilation has
recently been observed [18, 19]. Our study analyzed the
effects of ATP and analogs in preconstricted renal arteries
of rabbits and humans. The role of the endothelium and the
possible involvement of an endothelium-derived relaxing
factor in the vasodilator responses was examined.
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METHODS
Rabbit blood vessels
Intact segments of the rabbit main renal or femoral
arteries were obtained from rabbits of either sex (2.0 to 3.0
kg) that were killed by cervical dislocation. Portions of
about 1 to 2 cm of the arteries were dissected free from
surrounding connective tissue. In some experiments the
endothelium was removed mechanically by gentle rubbing
over a steel cannula.
Human blood vessels
The in vitro study was approved by the local ethics
committee. Renal blood vessels were obtained from male
and female patients (47 to 83 years of age) undergoing
renal surgery because of hypernephroma. Portions of about
1 to 2 cm of the arteries were dissected free from surround-
ing connective tissue.
Experimental procedure
The blood vessel segments were fixed between two steel
cannulas and placed in an organ bath (37°C) containing
Krebs-Henseleit solution (detailed below). The solution
was equilibrated with 95% O2/5% CO2 and perfused
through the organ bath at a rate of 0.66 ml/min. In addition
to the organ bath perfusion, the segments were perfused
intraluminally (0.5 ml/min rate). Both perfusion routes
were separate, and drugs were administered independently.
Outer vascular diameters were recorded continuously by a
photoelectric device [23]. The transmural pressure was
adjusted to 40 (rabbit blood vessels) or 50 (human blood
vessels) mm Hg and did not change during the experiment.
The arteries were preconstricted by the following drugs
added to the organ bath: rabbit blood vessels with norepi-
nephrine (0.4 mmol/liter); human blood vessels with either
norepinephrine (0.4 mmol/liter) or PGF2a (0.01 mmol/liter;
since vasodilator responses to ATP did not differ, results
were pooled). Adenosine, ATP, ADPbS, 2-methylthio-
adenosine-59-triphosphate sodium salt (2-MeSATP), ace-
tylcholine and sodium nitroprusside were given intralumi-
nally either at a single concentration or at increasing
concentrations in a cumulative manner. In a single prepa-
ration the concentration-response relationship was ana-
lyzed for only one agonist. Two dose-response curves were
performed for each agonist (adenosine, ATP, ADPbS,
2-MeSATP). When the effect of an antagonist or enzyme
blocker was tested, it was added 20 minutes before the
second agonist-response curve. In control experiments (no
antagonist) the first and second agonist curves did not
differ significantly (paired t-test; P . 0.05). The figures
show the second dose response curves in the presence and
absence of antagonists or enzyme blockers, added at a fixed
concentration to both the extra- and the intraluminal
solution. The drug-induced vasodilation was expressed as a
percentage decrease of the vasoconstrictor response to
norepinephrine or PGF2a. Where relevant, the sigmoid-
shaped function No. 25 of Waud [24] was fitted to the
averaged agonist concentration-response data. The func-
tion yielded the maximal vasodilator response and the EC50
concentration (that is, the concentration that caused 50%
of the maximal response).
Statistics
Means 6 SEM from at least three observations are given
throughout. Differences between means were tested for
significance by the Student’s t-test modified according to
Bonferroni. P , 0.05 or lower was taken as the criterion of
statistical significance. N is the number of preparations.
Drugs and vehicles
The following drugs were used: 2-methylthio-adenosine-
59-triphosphate sodium salt (2-MeSATP), pyridoxal-phos-
phate-6-azophenyl-29,49-disulphonic acid tetrasodium salt
(PPADS), reactive blue 2 sodium salt (RB 2), 8-p-(sulpho-
phenyl)theophylline (8-SPT) (Biotrend, Research Bio-
chemicals, Ko¨ln, Germany); acetylcholine chloride (ACh),
adenosine-59-O-(2-thiodiphosphate) (ADPbS) lithium salt,
indomethacin, NG-nitro-L-arginine, NG-nitro-L-arginine
methyl ester (L-NAME), (-)-norepinephrine HCl, prosta-
glandin F2a (PGF2a), sodium nitroprusside (SNP; Sigma,
Deisenhofen, Germany). Solutions of drugs were prepared
with either distilled water or in the case of indomethacin
with ethanol. The Krebs-Henseleit solution had the follow-
ing composition (mmol/liter): NaCl, 118; KCl, 4.7; CaCl2,
2.5; MgSO4, 0.45; NaHCO3, 25; KH2PO4, 1.03; glucose,
11.1; disodium EDTA, 0.07; ascorbic acid, 0.07 and (unless
stated otherwise) indomethacin, 0.01.
RESULTS
Rabbit renal arteries
Rabbit renal arteries were incubated and perfused with
Krebs-Henseleit solution containing indomethacin (10
mmol/liter). After an equilibration period of 60 minutes,
the average vessel diameter of arteries with intact endothe-
lium amounted to 1894 6 13 mm (N 5 203). Then, the
arteries were preconstricted by addition of norepinephrine
(0.4 mmol/liter) to the bath fluid for the remainder of the
experiment. Norepinephrine caused a decrease in the ves-
sel diameter of 492 6 5 mm. Drug induced dilation of each
blood vessel was expressed as a percentage of the respec-
tive vasoconstrictor response (restoring of the vessel diam-
eter prior to preconstriction equals 100% dilation). The
functional integrity of the endothelium was tested by an
intraluminal addition of a single concentration of acetyl-
choline (1 mmol/liter); acetylcholine caused an average
dilation of 93.6 6 0.3% (N 5 203).
Effects of purinoceptor agonists and interaction with
purinoceptor antagonists
Adenosine (0.03 to 1000 mmol/liter), ATP (0.01 to 100
mmol/liter), ADPbS (0.01 to 30 mmol/liter) as well as
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2-MeSATP (0.001 to 3 mmol/liter) added intraluminally in
a cumulative manner caused a concentration-dependent
vasodilation (Figs. 1 and 2). Adenosine and ATP increased
the vessel diameter almost to preconstriction values (100%
dilation); ADPbS and 2-MeSATP both caused dilation of
about 80% (Fig. 2). The respective EC50 values (half-
maximally effective concentrations) determined by non-
linear curve fitting were 1 mmol/liter (adenosine), 1 mmol/
liter (ATP), 0.4 mmol/liter (ADPbS) and 0.2 mmol/liter
(2-MeSATP).
Fig. 1. Vasodilation induced by adenosine and ATP in rabbit renal
arteries and their interaction with purinoceptor antagonists. Rabbit renal
arteries were incubated and perfused with Krebs-Henseleit solution at
37°C; vasoconstriction was induced by addition of norepinephrine (0.4
mmol/liter). Vasodilator responses were elicited by addition of adenosine
(A) or ATP (B) to the perfusion solution at increasing concentrations in a
cumulative manner. Vasodilator responses are expressed as percentage
decrease of the vasoconstrictor response to norepinephrine. In some
experiments the extra- and intraluminal solution contained 8-p-(sulpho-
phenyl)theophylline (8-SPT, 100 mmol/liter) or reactive blue 2 (RB2, 3
mmol/liter). N is the number of arteries tested: in A, Control (N 5 20),
8-SPT (N 5 10) RB2 (N 5 19); in B, Control (N 5 17), 8-SPT (N 5 7),
RB2 (N 5 10). Data points are means 6 SEM. Symbols are: (l) control;
(L) 8-SPT (100 mmol/liter); (f) RB2 (3 mmol/liter). *Significant treat-
ment effect of 8-SPT and RB2 (P , 0.05).
Fig. 2. Vasodilation induced by ADPbS and 2-MeSATP in rabbit renal
arteries and their interaction with purinoceptor antagonists. Vasodilator
responses were elicited by addition of ADPbS (A) or 2-MeSATP (B) to
the perfusion solution at increasing concentrations in a cumulative
manner. In some experiments the extra- and intraluminal solution con-
tained 8-p-(sulphophenyl)theophylline (8-SPT, 100 mmol/liter) or reactive
blue 2 (RB2, 3 mmol/liter). N is the number of arteries tested: in A,
Control (N 5 13), 8-SPT (N 5 8), RB2 (N 5 11); in B, 2-MeSATP (N 5
7), 8-SPT (N 5 7), RB2 (N 5 7). Data points are means 6 SEM.
*Significant treatment effect of 8-SPT or RB2 (P , 0.05). Symbols are:
(l) control; (L) 8-SPT 100 mmol/liter; (f) RB2 3 mmol/liter.
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Purinoceptor antagonists were added intra- and extralu-
minally 30 minutes before the second concentration-re-
sponse curve for an agonist was performed. The P1-
receptor antagonist 8-SPT (100 mmol/liter) [25] shifted the
concentration-response curves of adenosine, ATP and
ADPbS to the right (Figs. 1 and 2). The maximal effect of
ADPbS was decreased by 8-SPT. 8-SPT (100 mmol/liter) by
itself did not alter the vessel diameter (not shown).
Reactive blue 2 (3 mmol/liter), which preferentially
blocks P2Y-receptors in blood vessels [26], did not alter the
concentration-response curve of adenosine (Fig. 1A). Re-
active blue 2 slightly shifted the concentration-response
curves of ATP and ADPbS to the right (Figs. 1B and 2A;
significantly for ADPbS at 1 mmol/liter). The response to
2-MeSATP was markedly decreased by reactive blue 2 (Fig.
2B). Reactive blue 2 at a concentration of 3 mmol/liter by
itself did not change the vessel diameter; however, at a
concentration of 30 mmol/liter it caused vasoconstriction
(not shown) [26]. Therefore, the interaction of higher
concentrations of reactive blue 2 with purinoceptor ago-
nists could not be studied.
Some additional experiments using ATP as a purinocep-
tor agonist were performed in the presence of 8-SPT (100
mM) to avoid any interaction with P1-receptors. In these
experiments the preferential P2X-receptor antagonist
PPADS [27] shifted the concentration-response curve of
ATP to the left when it was added at a P2X-receptor-
selective concentration of 1 mmol/liter [27] (Fig. 3). PPADS
given at a much higher concentration of 30 mmol/liter
shifted the ATP concentration-response curve to the right
(Fig. 3).
Contribution of the endothelium and interaction with
L-NAME, nitro-L-arginine and indomethacin
Further experiments were performed to study the in-
volvement of the endothelium in the dilator responses to
purinoceptor agonists and to search for possible dilator
mediators. The endothelium from rabbit renal arteries was
mechanically removed. After the equilibration period of 60
minutes the average vessel diameter of these preparations
amounted to 1665 6 73 mm (N 5 18). Norepinephrine
caused a decrease in vessel diameter of 328 6 46 mm. The
maximal dilation induced by both adenosine and ATP was
markedly reduced by the removal of the endothelium (Fig.
4). The dilator response to acetylcholine (1 mmol/liter) was
attenuated in a similar manner. In contrast, in the same
endothelium denuded preparations the dilator response to
sodium nitroprusside was unchanged (Fig. 4) when com-
pared to its effect in intact preparations.
In renal arteries with intact endothelium the dilator
responses to adenosine and ATP were only slightly de-
creased by the nitric oxide synthase blocker L-NAME (300
mmol/liter; Fig. 5). However, the dilator response to 2-Me-
SATP was abolished by L-NAME (300 mmol/liter; Fig. 6A).
L-NAME markedly, albeit not completely, reduced the
vasodilator response to acetylcholine (Fig. 6B). Addition of
nitro-L-arginine (300 mmol/liter) as well as omission of
indomethacin caused no change in the vasodilator re-
sponses to adenosine and ATP (N 5 8 to 17; not shown).
Similar results were obtained in experiments performed
with rabbit femoral arteries with intact endothelium. The
average diameter of these vessels amounted to 1492 6 42
mm and norepinephrine caused a vasoconstrictor response
of 481 6 24 mm (N 5 25). L-NAME (300 mmol/liter) did
not affect the response to ATP but attenuated acetylcho-
line-induced vasodilation (not shown).
Human renal arteries
Human renal arteries were incubated and perfused as
described for rabbit arteries. After an equilibration period
of 60 minutes the average vessel diameter amounted to
2172 6 217 mm (N 5 10). The arteries were preconstricted
by addition of either prostaglandin PGF2a (0.01 mmol/liter;
decrease of the diameter by 492 6 39 mm; N 5 4) or
norepinephrine (0.4 mmol/liter; 543 6 58 mm; N 5 6) to the
bath fluid for the remainder of the experiment. ATP (0.03
to 300 mmol/liter) added intraluminally in a cumulative
manner caused a concentration-dependent vasodilation of
human renal arteries with an EC50 of about 1 mmol/liter
(Fig. 7). The maximal dilation induced by ATP amounted
to about 80%. 8-SPT (100 mmol/liter) shifted the concen-
tration response curve of ATP to the right. Acetycholine
given in a single concentration of 1 mmol/liter induced a
dilation of 47.2 6 12% (N 5 5).
Fig. 3. Vasodilation induced by ATP in the presence of 8-p-(sulphophe-
nyl)theophylline in rabbit renal arteries and its interaction with pyridox-
al-phosphate-6-azophenyl-2*,4*-disulphonic acid. Vasodilator responses
were elicited by addition of ATP to the perfusion solution at increasing
concentrations in a cumulative manner. In all experiments the extra- and
intraluminal solution contained 8-p-(sulphophenyl)theophylline (8-SPT,
100 mmol/liter); in some experiments the solution contained in addition
pyridoxal-phosphate-6-azophenyl-29,49-disulphonic acid (PPADS; 1 or 30
mmol/liter). N is the number of arteries tested: Control (N 5 8), PPADS
1 mmol/liter; N 5 10), PPADS 30 mmol/liter (N 5 8). Data points are
means 6 SEM. *Significant treatment effect of PPADS (P , 0.05). Symbols
are: (l) control; (M) PPADS 1 mmol/liter; (f) PPADS 30 mmol/liter.
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DISCUSSION
Vasodilation induced by adenosine and adenine
nucleotides in renal arteries
In renal tissues adenosine and adenine nucleotides orig-
inate from several sources. As in other sympathetically
innervated tissues ATP is released as a cotransmitter of
norepinephrine from postganglionic sympathetic nerves
[16, 28–34]. In the extracellular space ATP, thus released,
is broken down by ectonucleotidases to ADP, AMP and
adenosine [32, 34]. Another important source of extracel-
lular adenosine and adenine nucleotides are non-neuronal
cells including endothelial cells, which release these com-
pounds upon activation of membrane-bound receptors
including a1-adrenoceptors by specific but, in the case of
nucleotides, as yet unknown mechanisms [30, 35–39]. Apart
Fig. 4. Effect of removal of the endothelium on vasodilation induced by
adenosine and ATP in rabbit renal arteries. Vasodilator responses were
elicited by addition of adenosine (A) or ATP (B) to the perfusion solution
at increasing concentrations in a cumulative manner. In A, symbols are:
(l) adenosine; (L) adenosine (-Endoth.). In B, symbols are: (l ATP;
(L) ATP (-Endoth.); (f) ACH; (M) ACH (-Endoth.); (E) SNP. In some
experiments the endothelium was mechanically destroyed (-Endoth.).
Acetylcholine (ACh) or sodium nitroprusside (SNP) were added at a
single concentration to test for the destruction of the endothelium and for
the viability of the preparation. N is the number of arteries tested: in A,
adenosine (N 5 20), adenosine (-Endoth.; N 5 9), in B, ATP (N 5 17),
ATP (-Endoth.; N 5 9), ACh (N 5 44), ACh (-Endoth.; N 5 9), SNP (N 5
44). Data points are means 6 SEM. *Significant effect of destruction of the
endothelium (P , 0.05).
Fig. 5. Vasodilation induced by adenosine and ATP in rabbit renal
arteries and their interaction with NG-nitro-L-arginine methyl ester.
Vasodilator responses were elicited by addition of adenosine (A) or ATP
(B) to the perfusion solution at increasing concentrations in a cumulative
manner. In some experiments the extra- and intraluminal solution con-
tained NG-nitro-L-arginine methyl ester (L-NAME, 300 mmol/liter). N is
the number of arteries tested: in A, Control (N 5 20; l)), L-NAME (N 5
8; L); in B, Control (N 5 17; l), L-NAME (N 5 8; L). Data points are
means 6 SEM. *Significant treatment effect of L-NAME (P , 0.05).
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from these physiological release mechanisms, renal isch-
emia and acute renal failure are pathophysiological condi-
tions that may cause a cellular loss of ATP and adenosine
due to structural damage [1, 3].
Thus, adenosine and adenine nucleotides are important
endogenous regulators of renal blood flow. Therefore, the
present study analyzed the receptors, their cellular location
and the possible mediators involved in the vasodilator
responses to adenosine and adenine nucleotides in renal
arteries. Our results demonstrate that ATP and ATP
analogs dilate rabbit and human renal arteries in the same
manner as shown previously for rat renal blood vessels
[17–19]. ATP-induced dilator responses in rabbit and hu-
man renal arteries were similar or even greater (human) in
size to those induced by acetylcholine, demonstrating the
significance of adenine nucleotides in the modulation of
renal vascular tone. It is noteworthy that in rabbit renal
arteries adenosine was equally effective as ATP. Both
compounds dilated the vessels by almost 100% with iden-
tical half-maximal concentrations of about 1 mmol/liter.
Our findings of such a potent vasodilator action of ATP and
adenosine are valid for larger human and rabbit renal
arteries. In smaller renal blood vessels, which are the
primary sites of renovascular resistance, the vasoconstric-
tory effect of ATP may dominate [5]. Furthermore, the
response to both agonists will also depend on the vessel
tone. In afferent arterioles of rats [5, 6], the rabbit kidney
[40] and human renal as well as cutaneous blood vessels
[20, 38] not preconstricted as in the present study, exoge-
nous ATP induces a dose dependent contraction.
P1-receptors
Adenosine is known to cause dilation of blood vessels by
an interaction with P1-receptors of the adenosine A2-
subtype. In agreement with this view, in rabbit renal
Fig. 6. Vasodilation induced by 2-MeSATP and acetylcholine in rabbit
renal arteries and their interaction with NG-nitro-L-arginine methyl
ester. Vasodilator responses were elicited by addition of by addition of
2-MeSATP (A; 2-MeSATP) or acetylcholine (B; ACh) to the perfusion
solution at increasing concentrations in a cumulative manner. In some
experiments the extra- and intraluminal solution contained NG-nitro-L-
arginine methyl ester (L-NAME, 300 mmol/liter). N is the number of
arteries tested; in A, Control (N 5 7; l), L-NAME (N 5 7; L); in B, ACh
(N 5 5; l), L-NAME (N 5 5; L). Data points are means 6 SEM.
*Significant treatment effect of L-NAME (P , 0.05). For further details
see legend of Figure 1.
Fig. 7. Vasodilation induced by ATP in human renal arteries and its
interaction with 8-p-(sulphophenyl)theophylline (8-SPT). Human renal
arteries were incubated and perfused with Krebs-Henseleit solution at
37°C; vasoconstriction was induced by addition of norepinephrine (0.4
mmol/liter) or prostaglandin F2a (0.01 mmol/liter). Vasodilator responses
were elicited by the addition of ATP to the perfusion solution at increasing
concentrations in a cumulative manner. Vasodilator responses are ex-
pressed as percentage decrease of the vasoconstrictor response. In some
experiments the extra- and intraluminal solution contained 8-SPT (100
mmol/liter). N is the number of arteries tested: Control (N 5 6; l), 8-SPT
100 mmol/liter (N 5 6; L). Data points are means 6 SEM. *Significant
treatment effect of 8-SPT (P , 0.05).
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arteries responses to adenosine were attenuated by the
P1-receptor antagonist 8-SPT, but not by the P2-receptor
antagonist reactive blue 2. The major part of the responses
to ATP in the rabbit as well as in the human renal artery is
also likely to be mediated by activation of P1-receptors, as
indicated by the antagonistic effect of 8-SPT on the ATP
responses in both species. It is feasible that adenosine
derived from the breakdown of ATP mediates this effect.
This may not occur to the same extent with endogenous
neuronally released ATP, however, we have not tested this
possibility. An additional explanation for the inhibitory
effect of 8-SPT may be that ATP directly activates P1-
receptors as previously shown for adenine nucleotides in
some preparations [41].
P2-receptors
P2-receptors, activated by ATP, are divided in P2X- and
P2Y-receptor subtypes, which represent a complex and
powerful pressor/depressor control system of vascular tone
in many species. In rabbit renal arteries the preferential
P2Y-agonists ADPbS and 2-MeSATP both induced potent
dilator responses. The dilator effects of 2-MeSATP and to
a lesser extent that of ADPbS were attenuated by reactive
blue 2, used at a concentration of 3 mmol/liter, which is
selective for vascular P2Y-receptors [26]. Reactive blue 2
did not change the response to adenosine. Hence, the
present study clearly demonstrates the involvement of
P2Y-receptors in the vasodilator action of these adenine
nucleotides in rabbit renal arteries, findings that are in
agreement with observations recently obtained in rat kid-
ney [17–19]. ATP, the endogenous agonist, at P2-receptors
dilated human and rabbit renal arteries; however, this
effect was largely sensitive to P1-receptor antagonism.
Since a simultaneous activation of P2X- and P2Y-receptors
by ATP may ameliorate the dilator action of ATP as well,
the effect of the preferential P2X-receptor antagonist
PPADS was tested in rabbit renal arteries in the presence
ot the P1-receptor antagonist 8-SPT. PPADS, when used at
a low P2X-selective concentration of 1 mmol/liter, shifted
the concentration-response curve of ATP to the left. This
potentiation of the dilator response to ATP by PPADS (1
mmol/liter) is likely due to preventing the vasoconstrictor
action of ATP at P2X-receptors. In addition, PPADS may
inhibit ATP breakdown, thus favoring P2Y-mediated vaso-
dilation [42]. PPADS at a higher concentration of 30
mmol/liter shifted the concentration-response curve of ATP
to the right since at this concentration it also blocks
P2Y-receptors [27].
Endothelium and relaxing factors
The present study shows that in rabbit renal artery the
vasodilation evoked by ATP and adenosine is to a large
extent dependent on the presence of intact endothelium.
This allows two conclusions. First, P1- and P2-receptors are
located on endothelial cells, and second, an endothelium-
derived relaxing factor mediates the dilator actions of ATP
and adenosine. The prominent role of the endothelium in
purine-evoked dilation has been previously shown in many
blood vessels [2, 22]. However, in some blood vessels such
as the rabbit mesenteric artery [43], receptors mediating
adenosine and adenine nucleotide-induced relaxation seem
to be located on smooth muscle cells.
The majority of our experiments were performed in the
presence of the cyclooxygenase inhibitor indomethacin,
which has been shown to prevent ATP induced formation
of prostaglandins [40]. It was evident that the absence or
presence of indomethacin did not make any difference for
the dilator responses to ATP and to adenosine. Hence,
prostaglandins were not the endothelium-derived relaxing
factors mediating the dilator responses to ATP and aden-
osine. In many cases this factor is nitric oxide since nitric
oxide synthase blockers abolish the purinoceptor-mediated
vasodilation [44, 45]. Accordingly, in the rabbit renal artery
the dilatory effect the selective P2Y-receptor agonist 2-
MeSATP was entirely due to the formation and release of
nitric oxide. In contrast, a relaxing factor distinct from
nitric oxide mediates the major component of ATP and
adenosine induced vasodilation. This was shown by the
failure of two nitric oxide synthase blockers, namely L-
NAME and nitro-L-arginine, to markedly reduce the ATP-
and adenosine evoked endothelium dependent dilation,
which was exerted in both cases by activation of P1-
receptors. Such a resistance to L-NAME was also observed
with acetylcholine: In rabbit renal and femoral arteries
there was no complete blockade of the acetylcholine-
induced dilator responses by L-NAME. These findings are
in agreement with recent observations indicating the in-
volvement of both nitric oxide and another yet unknown
factor in acetylcholine induced relaxation of rabbit renal
arteries [46]. The occurrence of an endothelium-derived
relaxing factor distinct from nitric oxide (such as, endothe-
lium-derived hyperpolarizing factor) has been described in
other blood vessels including mesenteric, coronary and
carotid arteries [46–50]. However, in contrast to our cur-
rent study and the above-cited results, in rat kidney vaso-
dilation induced by adenosine and adenine nucleotides was
shown to be largely dependent on nitric oxide [11, 18, 51].
Thus, our data suggest that endothelial cells utilize relaxing
factors to a different degree when activated by distinct cell
surface receptors: in rabbit renal and femoral arteries
P1-receptor activation by adenosine, in comparison to
acetylcholine and P2Y-receptor activation by 2-MeSATP,
favor the involvement of nitric oxide-independent mecha-
nisms.
Conclusions
The present study analyzes the dilator actions of adeno-
sine and adenine nucleotides in rabbit and human renal
arteries. The results show that (1) rabbit renal arteries
possess P1- as well as P2Y-receptors, both of which are
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involved in the dilator action of nucleotides; (2) the dilator
effects of adenosine and adenine nucleotides are
endothelium dependent and rely on the generation of
endothelium-derived relaxing factors; (3) neither nitric
oxide nor prostaglandins are the dominant mediators of
adenosine P1-receptor mediated dilation; and (4) P2-re-
ceptor mediated dilation in rabbit renal arteries is nitric
oxide dependent; (5) in the human renal artery ATP
induces dilation, an effect mediated to a great extent by
P1-receptors. We anticipate that ATP modulation of renal
blood flow by nitric oxide dependent and independent
mechanisms may be a field for future pharmacotherapeutic
interventions.
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APPENDIX
Abbreviations used in this article are: ACh, acetylcholine chloride;
ADPBS, adenosine-59-O-(2-thiodiphosphate); ATP, adenosine triphos-
phate; L-NAME, NG-nitro-L-arginine methyl ester; 2-MeSATP, 1-meth-
ylthio-adenosine-59-triphosphate sodium salt; PGF2a, prostaglandin-2a;
PPADS, pyridoxal-phosphate-6-azophenyl-29,49-disulphonic acid tetraso-
dium salt; RB2, reactive blue 2 sodium salt; SNP, sodium nitroprusside;
8-SPT, 8-p-(sulphenyl)theophylline.
REFERENCES
1. CHURCHILL PC, BIDANI AK: Adenosine and renal function, in Aden-
osine and Adenosine Receptors, edited by WILLIAMS M, Clifton,
Humana Press, 1990, pp 335–380
2. OLSSON RA, PEARSON JD: Cardiovascular purinoceptors. Physiol Rev
70:761–845, 1990
3. OSSWALD H, MU¨HLBAUER B, SCHENK F: Adenosine mediates tubulo-
glomerular feedback response: An element of metabolic control of
kidney function. Kidney Int 39(Suppl 32):S128–S131, 1991
4. SPIELMAN WS, AREND LJ: Adenosine receptors and signaling in the
kidney. Hypertension 17:117–130, 1991
5. INSCHO EW, MITCHELL KD, NAVAR LG: Extracellular ATP in the
regulation of renal microvascular function. FASEB J 8:319–328, 1994
6. NAVAR LG, INSCHO EW, MAJID DSA, IMIG JD, HARRISON-BERNARD
LM, MITCHELL KD: Paracrine regulation of the renal microcircula-
tion. Physiol Rev 76:425–536, 1996
7. CHURCHILL PC, BIDANI A: Renal effects of selective adenosine
receptor agonists in anesthetized rats. Am J Physiol 252:F299–F303,
1987
8. CHURCHILL PC, ELLIS VR: Purinergic P2Y receptors stimulate renin
secretion by rat renal cortical slices. J Pharmacol Exp Ther 266:160–
163, 1993a
9. HOLZ FG, STEINHAUSEN M: Renovascular effects of adenosine recep-
tor agonists. Ren Physiol 10:272–282, 1987
10. WEIHPRECHT H, LORENZ JN, BRIGGS JP, SCHNERMANN J: Vasomotor
effects of purinergic agonists in isolated rabbit afferent arterioles.
Am J Physiol 263:F1026–F1033, 1992
11. MARTIN PL, POTTS AA: The endothelium of the rat renal artery plays
an obligatory role in A2 adenosine receptor-mediated relaxation
induced by 59-N-ethylcarboxamidoadenosine and N6-cyclopentylad-
enosine. J Pharmacol Exp Ther 270:893–899, 1994
12. INSCHO EW, CARMINES PK, NAVAR LG: Juxtamedullary afferent
arteriolar responses to P1 and P2 purinergic stimulation. Hypertension
17:1033–1037, 1991
13. BARNARD EA, BURNSTOCK G, WEBB TE: The G-protein coupled
receptors for ATP and other nucleotides: A new receptor family.
Trends Pharmacol Sci 15:67–70, 1994
14. SURPRENANT A, BUELL G, NORTH RA: P2X receptors bring new
structure to ligand gated ion channels. Trends Neurosci 18:224–229,
1995
15. INSCHO EW, OHISHI K, NAVAR LG: Effects of ATP on pre- and
postglomerular juxtamedullary microvasculature. Am J Physiol 263:
F886–F893, 1992
16. RUMP LC, WILDE K, SCHOLLMEYER P: Prostaglandin E2 inhibits
noradrenaline release and purinergic pressor responses to renal nerve
stimulation at 1 Hz in isolated kidneys of young spontaneously
hypertensive rats. J Hypertens 8:897–908, 1990
17. CHURCHILL PC, ELLIS VR: Pharmacological characterization of the
renovascular P2 purinergic receptors. J Pharmacol Exp Ther 265:334–
338, 1993b
18. ELTZE M, ULLRICH B: Characterization of vascular P2-purinoceptors
in the rat isolated perfused kidney. Eur J Pharmacol 306:139–152,
1996
19. VARGAS F, MORENO MRR, OSUNA A: Renal vascular reactivity to
ATP in ageing rats. Med Sci Res 24:263–265, 1996
20. VON KU¨GELGEN I, KRUMME B, SCHAIBLE U, SCHOLLMEYER PJ, RUMP
LC: Vasoconstrictor responses to the P2X-purinoceptor agonist b,g-
methylene-L-ATP in human cutaneous and renal blood vessels. Br J
Pharmacol 116:1932–1936, 1995
21. BURNSTOCK G, KENNEDY C: Is there a basis for distinguishing two
types of P2-purinoceptor? Gen Pharmac 16:433–440, 1985
22. RALEVIC V, BURNSTOCK G: Roles of P2-purinoceptors in the cardio-
vascular system. Circulation 84:1–14, 1991
23. GALLE J, BASSENGE E, BUSSE R: Oxidized low density lipoproteins
potentiate vasoconstrictions to various agonists by direct interaction
with vascular smooth muscle. Circ Res 66:1287–1293, 1990
24. WAUD DR: Analysis of dose-response relationships, in Advances in
General and Cellular Pharmacology, edited by NARAHASHI T, BIANCHI
CP, New York, Plenum Press, 1976, pp 145–178
25. WILLIAMS M, BRAUNWALDER A, ERICKSON TJ: Evaluation of the
binding of the A-1 selective adenosine radioligand, cyclopentylad-
enosine (CPA), to rat brain tissue. Naunyn-Schmiedeberg’s Arch
Pharmacol 332:179–183, 1986
26. BURNSTOCK G, WARLAND JJI: P2-purinoceptors of two subtypes in the
rabbit mesenteric artery: Reactive blue 2 selectively inhibits responses
mediated via the P2Y- but not the P2X-purinoceptor. Br J Pharmacol
90:383–391, 1987
27. WINDSCHEIF U, RALEVIC V, BAUMERT HG, MUTSCHLER E, LAMBRE-
CHT G, BURNSTOCK G: Vasoconstrictor and vasodilator responses to
various agonists in the rat perfused mesenteric arterial bed: Selective
inhibition by PPADS of contractions mediated via P2x-purinoceptors.
Br J Pharmacol 113:1015–1021, 1994
28. SCHWARTZ DD, MALIK KU: Renal periarterial nerve stimulation-
induced vasoconstriction at low frequencies is primarily due to release
of a purinergic transmitter in the rat. J Pharmacol Exp Ther 250:764–
771, 1989
29. RUMP LC, WILDE K, BOHMANN C, SCHOLLMEYER P: Effects of the
novel dopamine DA2-receptor agonist carmoxirole (EMD 45609) on
noradrenergic and purinergic neurotransmission in rat isolated kid-
ney. Naunyn-Schmiedeberg’s Arch Pharmacol 345:300–308, 1992
30. BOHMANN C, RUMP LC, SCHAIBLE U, VON KU¨GELGEN I: a-Adreno-
ceptor modulation of norepinephrine and ATP release in isolated
kidneys of spontaneously hypertensive rats. Hypertension 25:1224–
1231, 1995
31. BOHMANN C, VON KU¨GELGEN I, RUMP LC: P2-Receptor modulation of
noradrenergic neurotransmission in rat kidney. Br J Pharmacol (in
press)
32. BURNSTOCK G: Co-transmission. Arch Int Pharmacodyn 304:7–33,
1990
33. VON KU¨GELGEN I, STARKE K: Noradrenaline-ATP co-transmission in
the sympathetic nervous system. Trends Pharmacol Sci 12:319–324,
1991
34. ZIMMERMANN H: Signalling via ATP in the nervous system. Trends
Neurosci 17:420–426, 1994
Rump et al: Purinoceptors and renal vasodilation480
35. FREDHOLM BB, HEDQVIST P: Release of 3H-purines from [3H]-
adenine labelled rabbit kidney following sympathetic nerve stimula-
tion:and its inhibition by alpha-adrenoceptor blockage. Br J Pharma-
col 64:239–245, 1978
36. PEARSON JD, GORDON JL: Vascular endothelium and smooth muscle
cells selectively release adenine nucleotides. Nature 281:384–386, 1979
37. SEDAA KO, BJUR RA, SHINOZUKA K, WESTFALL DP: Nerve and
drug-induced release of adenine nucleosides and nucleotides from
rabbit aorta. J Pharmacol Exp Ther 252:1060–1067, 1990
38. RUMP LC, VON KU¨GELGEN I: A study of ATP as a sympathetic
cotransmitter in human saphenous vein. Br J Pharmacol 111:65–72,
1994
39. YANG S, CHEEK DJ, WESTFALL DP, BUXTON IL: Purinergic axis in
cardiac blood vessels. Agonist-mediated release of ATP from cardiac
endothelial cells. Circ Res 74:401–407, 1994
40. NEEDLEMAN P, MINKES MS, DOUGLAS JR: Stimulation of prosta-
glandin biosynthesis by adenine nucleotides. Circ Res 34:455– 460,
1974
41. BAILEY SJ, HICKMAN D, HOURANI SMO: Characterization of P1-
purinoceptors mediating contraction of the rat colon muscularis
mucosae. Br J Pharmacol 105:400–404, 1992
42. CRACK BE, BEUKERS MW, MCKECHNIE KCW, IJZERMAN AP, LEFF P:
Pharmacological analysis of ecto-ATPase inhibition: Evidence for
combined enzyme inhibition and receptor antagonism in P2X-purino-
ceptor ligands. Br J Pharmacol 113:1432–1438, 1994
43. MATHIESON JJI, BURNSTOCK G: Purine-mediated relaxation and con-
striction of isolated rabbit mesenteric artery are not endothelium-
dependent. Eur J Pharmacol 118:221–229, 1985
44. SCHMIDT HHHW, NAU H, WITTFOHT W, GERLACH J, PRESCHER KE,
KLEIN MM, NIROOMAND F, BOEHME E: Arginine is a physiological
precursor of endothelium-derived nitric oxide. Eur J Pharmacol
154:213–216, 1988
45. BOGLE RG, COADE SB, MONCADA S, PEARSON JD, MANN GE:
Bradykinin and ATP stimulate L-arginine uptake and nitric oxide
release in vascular endothelial cells. Biochem Biophys Res Com
180:926–932, 1991
46. KITAGAWA S, YAMAGUCHI Y, KUNITOMO M, SAMESHIMA E, FUJIWARA
M: NG-nitro-L-arginine-resistant endothelium-dependent relaxation
induced by acetylcholine in the rabbit renal artery. Life Sci 55:491–
498, 1994
47. ILLIANO S, NAGAO T, VANHOUTTE PM: Calmidazolium, a calmodulin
inhibitor, inhibits endothelium-dependent relaxations resistant to
nitro-L-arginine in the canine coronary artery. Br J Pharmacol 107:
387–392, 1992
48. NAGAO T, ILLIANO S, VANHOUTTE PM: Heterogeneous distribution of
endothelium-dependent relaxations resistant to NG-nitro-L-arginine
in rats. Am J Physiol 263:H1090–H1094, 1992
49. COWAN CL, PALACINO JJ, NAJIBI S, COHEN RA: Potassium channel-
mediated relaxation to acetylcholine in rabbit arteries. J Pharmacol
Exp Ther 266:1482–1489, 1993
50. ZYGMUNT PM, GRUNDEMAR L, HOGESTATT ED: Endothelium-depen-
dent relaxation resistant to N omega-nitro-L-arginine in the rat
hepatic artery and aorta. Acta Physiol Scand 152:107–114, 1994
51. RADERMACHER J, FO¨RSTERMANN U, FRO¨LICH JC: Endothelium-de-
rived relaxing factor influences renal vascular resistance. Am J Physiol
259:F9–F17, 1990
Rump et al: Purinoceptors and renal vasodilation 481
